Literature DB >> 23018874

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.

Maisa Yoshimoto1, Keyue Ding, Joan M Sweet, Olga Ludkovski, Greg Trottier, Kyu S Song, Anthony M Joshua, Neil E Fleshner, Jeremy A Squire, Andrew J Evans.   

Abstract

Prostatic adenocarcinoma is an epithelial malignancy characterized by marked histological heterogeneity. It most often has a multifocal distribution within the gland, and different Gleason grades may be present within different foci. Data from our group and others have shown that the genomic deletion of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor gene and the disruption of the ETS gene family have a central role in prostate cancer and are likely to be associated with Gleason grade. In this study, prostate cancer samples were systematically analyzed to determine whether there was concordance between PTEN losses and TMPRSS2-ERG fusion rearrangements, within or between foci in multifocal disease, using well-annotated tissue microarrays (TMAs) consisting of 724 cores derived from 142 radical prostatectomy specimens. Three-color fluorescence in situ hybridization analysis of both the PTEN deletion and the TMPRSS2-ERG fusion was used to precisely map genetic heterogeneity, both within and between tumor foci represented on the TMA. PTEN deletion was observed in 56 of 134 (42%) patients (hemizygous=42 and homozygous=14). TMPRSS2-ERG fusion was observed in 63 of 139 (45%) patients. When analyzed by Gleason pattern for a given TMA core, PTEN deletions were significantly associated with Gleason grades 4 or 5 over grade 3 (P<0.001). Although TMPRSS2-ERG fusions showed a strong relationship with PTEN deletions (P=0.007), TMPRSS2-ERG fusions did not show correlation with Gleason grade. The pattern of genetic heterogeneity of PTEN deletion was more diverse than that observed for TMPRSS2-ERG fusions in multifocal disease. However, the marked interfocal discordance for both TMPRSS2-ERG fusions and PTEN deletions was consistent with the concept that multiple foci of prostate cancer arise independently within the same prostate, and that individual tumor foci can have distinct patterns of genetic rearrangements.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23018874     DOI: 10.1038/modpathol.2012.162

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  34 in total

1.  Heterogeneity of DNA methylation in multifocal prostate cancer.

Authors:  Inga Serenaite; Kristina Daniunaite; Feliksas Jankevicius; Arvydas Laurinavicius; Donatas Petroska; Juozas R Lazutka; Sonata Jarmalaite
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

2.  In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.

Authors:  C G Picanço-Albuquerque; C L Morais; F L F Carvalho; S B Peskoe; J L Hicks; O Ludkovski; T Vidotto; H Fedor; E Humphreys; M Han; E A Platz; A M De Marzo; D M Berman; T L Lotan; J A Squire
Journal:  Virchows Arch       Date:  2016-02-09       Impact factor: 4.064

3.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

4.  Near-infrared fluorescent digital pathology for the automation of disease diagnosis and biomarker assessment.

Authors:  Summer L Gibbs; Elizabeth Genega; Jeffery Salemi; Vida Kianzad; Haley L Goodwill; Yang Xie; Rafiou Oketokoun; Parmeshwar Khurd; Ali Kamen; John V Frangioni
Journal:  Mol Imaging       Date:  2015       Impact factor: 4.488

5.  SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.

Authors:  Kuo-Cheng Huang; Andrew Evans; Bryan Donnelly; Tarek A Bismar
Journal:  Pathol Oncol Res       Date:  2016-10-13       Impact factor: 3.201

6.  Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.

Authors:  Xiaoyu Qu; Claudio Jeldres; Lena Glaskova; Cynthia Friedman; Sarah Schroeder; Peter S Nelson; Christopher Porter; Min Fang
Journal:  J Mol Diagn       Date:  2016-01-02       Impact factor: 5.568

Review 7.  Prognostic prostate tissue biomarkers of potential clinical use.

Authors:  Theodorus H Van der Kwast
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 8.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

9.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

10.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.